Immunomedics Provides Blockbuster Breast Cancer Survival Data

Immunomedics Provides Blockbuster Breast Cancer Survival Data

Results from a study of Trodelvy presented over the weekend suggest Gilead Sciences' $21 billion buyout offer was a smart move.